Thermo Fisher Scientific Inc.

NYSE:TMO

Medical - Diagnostics & Research

Healthcare
$692.74 +0.96%

+$4.45 today

Market cap
$256.67B
Beta
0.87
P/E (TTM)
25.3
EPS (TTM)
$18.44
Dividend yield
0.39%
52W Low $390.50High $643.99

Volume 1.99M

Average 2.23M

TMO Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Thermo Fisher Scientific Inc.NYSE: TMO

Deferred Revenue · Q3 FY2026 · quarter ended Sep 2026

Deferred revenue remains negative

Q3 FY2026 deferred revenue was $0, compared with $2.85B a year earlier. Over 3 fiscal years it compounded at +1.4% a year.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q3 FY2026, down 2.8 pp from a year earlier.
  • Deferred revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$2.71B-5.0% YoY
Year agoSep 2025
$2.85B-100.0% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-5.0%——
3-year CAGR+1.4%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
2.71B USD
Year-over-year change
-5.0%
4-year CAGR
+0.5%

Deferred Revenue vs competitors

How TMO compares with its peers on the latest reported figures

  • TMO's Sep 2026 deferred revenue of $0 is the 7th highest of the 10 companies compared; the peer median is $82.9M.
  • Its year-over-year change of -100.0% is the lowest of 6, against a peer median of +4.3%.
  • Deferred revenue amounts to 0.0% of total assets for TMO, versus a peer median of 1.4%.
TMO Competitors Peer median
Deferred Revenue for TMO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AAgilent Technologies, Inc.Jul 2026$640M +3.2%+10.6%4.6%
WATWaters CorporationJul 2026$495M +48.3%+5.4%2.0%
BRKRBruker CorporationJun 2026$444.6M -7.0%+6.0%7.3%
MTDMettler-Toledo International Inc.Jun 2026$257.48M +5.6%+6.0%7.0%
QGENQiagen N.V.Jun 2026$82.9M ——1.4%
TECHBio-Techne CorporationSep 2026$31.76M +4.3%+16.1%1.2%
TMOThermo Fisher Scientific Inc.Sep 2026$0 -100.0%+1.4%0.0%
DHRDanaher CorporationSep 2026$0 ——0.0%
RVTYRevvity, Inc.Jul 2026$0 ——0.0%
BIOBio-Rad Laboratories, Inc.Jun 2026$0 ——0.0%
Peer median (excluding TMO) $82.9M+4.3%+6.0%1.4%

Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.48B8.52B8.08B4.02B9.85B
Short-term Investments0001.56B253M
Net Receivables8.95B9.43B9.66B9.63B10.57B
Inventory5.05B5.63B5.09B4.98B5.43B
Other Current Assets1.64B1.64B1.76B1.95B2.61B
Total Current Assets20.11B25.23B24.59B22.14B28.71B
Property, Plant & Equipment (Net)9.86B10.87B11B10.8B10.57B
Goodwill41.92B41.2B44.02B45.85B49.36B
Intangible Assets20.15B17.48B16.67B15.53B15.84B
Long-term Investments73M155M59M560M0
Tax Assets00000
Other Non-current Assets3B2.22B2.38B2.44B5.87B
Total Non-current Assets75.01B71.93B74.14B75.18B81.64B
Total Assets95.12B97.15B98.73B97.32B110.34B
Account Payables2.87B3.38B2.87B3.08B3.62B
Short-term Debt2.8B5.85B3.87B2.48B3.53B
Tax Payables00000
Deferred Revenue2.66B2.6B2.69B2.85B2.71B
Other Current Liabilities2.68B3.08B2.98B2.94B0
Total Current Liabilities13.44B17.01B14.01B13.33B15.19B
Long-term Debt32.15B28.91B31.31B29.06B35.85B
Deferred Tax Liabilities3.84B2.85B1.92B1.27B1.49B
Deferred Revenue (Non-current)1.24B1.18B1.5B1.14B0
Other Non-current Liabilities2.1B1.75B1.9B1.61B4.27B
Total Non-current Liabilities40.71B36B37.87B34.32B41.62B
Total Liabilities54.15B53.01B51.88B47.65B56.81B
Common Stock439M441M442M444M445M
Retained Earnings35.43B41.91B47.36B53.1B59.16B
Accumulated OCI(2.33B)(3.1B)(3.22B)(2.7B)(2.45B)
Other Stockholders Equity000(1M)0
Minority Interest184M170M107M87M129M
Total Equity40.98B44.15B46.84B49.67B53.54B
Total Debt36.34B36.07B36.42B32.78B39.39B
Net Debt31.86B27.55B28.34B28.77B29.53B

Thermo Fisher Scientific Inc.

NYSE:TMO

Intrinsic Alpha fair value

Locked

Current Price

$692.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.